The University of Pennsylvania Health System, part of the $11.1 billion Penn Medicine enterprise, is adding a seventh hospital to its brand with a planned acquisition of Doylestown Health, in Bucks County.

Doylestown Health’s flagship site Doylestown Hospital is part of the Penn Cancer Network, a group of hospitals and physician practices throughout the Greater Philadelphia area working with Penn Medicine’s Abramson Cancer Center to improve patient access to treatment and clinical trials. In 2011, UPHS opened Penn Radiation Oncology at Doylestown, where it today cares for more than 400 cancer patients annually.

Signing a letter of intent to integrate, Doylestown Health and UPHS told the public that combining will allow them to build on this existing relationship as well as develop new clinical programs and better services in hospitals, outpatient care facilities, in homes, and for telemedicine.

“We are excited to explore this opportunity with Doylestown Health, which has a strong, historic commitment to patients in the Northern region of the areas we serve,” said UPHS CEO Kevin Mahoney, in a statement.

Over the past decade, UPHS has expanded from a three-hospital system to six with the acquisitions of Chester County Hospital, Lancaster General Health, and Princeton Health in 2013, 2015, and 2018. Its three Philadelphia sites include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, and Pennsylvania Hospital.

Its additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Doylestown Hospital is a not-for-profit, community teaching hospital with 247 beds and has a medical staff of more than 435 physicians in over 50 specialties. It will provide UPHS clinicians and patients with access to these specialists as well as advanced treatments, minimally invasive surgical procedures, new clinical trials, and patient-centered care in state-of-the-art facilities.

“As we begin our second century, our boards of trustees are excited about how this partnership with Penn Medicine will further expand Doylestown Health’s ability to deliver clinical excellence and positively impact the health and well-being of the communities we have faithfully served for more than 100 years,” said Doylestown Health president and CEO James Brexler.

The acquisition is subject to review by both federal and state regulators.

Financial details were not disclosed.

Business Affairs Homepage